Skip to main content

Advertisement

Table 1 Patient Demographics

From: MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

  IMP321 No IMP321
N (%) N (%)
Age
Median 49.5 56.8
Range 35-73 48-70
Gender
Male 3 (50%) 4 (66.6%)
Female 3 (50%) 2 (33.3%)
ECOG PS
0 4 (66.6%) 5 (83.3%)
1 2 (33.3%) 1 (16.6%)
M sub-stage
M1a 3 (50%) 1 (16.6%)
M1b 1 (16.6%) 1 (16.6%)
M1c 2 (33.3%) 4 (66.6%)
Previous therapy for Stage IV
Surgery 1 (16.6%) 2 (33.3%)
CHT or RT 2 (33.3%) 1 (16.6%)
Other 2 (33.3%) 0 (0%)
Adjuvant immunotherapy
Yes 6 (100%) 6 (100%)
No 0 (0%) 0 (0%)